ArticleJournal of translational medicine2026
Analysis of tumor stem cell recruitment and integration in microvascular architectural heterogeneity during oral mucosal carcinogenesis: an in vivo experimental study.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTumor stem cells (TSCs) play a central role in oral mucosal carcinogenesis by promoting tumor growth, invasion, and angiogenesis. Microvascular architectural phenotype heterogeneity (MAPH) and vasculogenic mimicry (VM) contribute to vascular complexity within tumors and resistance to conventional anti-angiogenic therapies. However, the mechanisms through which TSCs influence MAPH and VM formation during oral mucosal carcinogenesis remain poorly understood. In this study, we aimed to investigate the role of TSCs in mediating MAPH and VM throughout oral mucosal carcinogenesis.
methodsAnimal models representing normal mucosa, precancerous lesions, and high-differentiated, moderate-differentiated, and low-differentiated squamous carcinomas were established. TSCs derived from HSC4 cells (isolated through laser capture microdissection (LCM) and validated using stemness markers and sphere-forming assays) were injected into the experimental models. Data were analyzed using one-way analysis of variance (ANOVA) and nonparametric tests, with multiple testing correction applied for proteomic analyses.
resultsMicrovascular morphology analysis revealed stage-specific heterogeneity. In the TSC-treated groups, fused morphology predominated in the precancerous and highly differentiated stages, budding morphology appeared in the moderately differentiated stage, and finger-like morphology was characteristic of the poorly differentiated stage. LCM proteomics identified 2,215 differential proteins, with angiopoietin-like protein 2 (ANGPTL2), cytokeratin 15 (CK15), and eukaryotic translation elongation factor 1 epsilon 1 (EEF1E1) as key candidates. In the TSC-treated groups, CK15 was upregulated, whereas ANGPTL2 and EEF1E1 were downregulated. In the control groups, CK15 gradually increased across stages, ANGPTL2 peaked in highly differentiated carcinomas, and EEF1E1 peaked in moderately differentiated carcinomas. TSCs intervention shifted ANGPTL2 and EEF1E1 peaks to the precancerous and highly differentiated stages, respectively.
conclusionsThese findings suggest that targeting these molecules may provide novel anti-angiogenic strategies for preventing or treating oral mucosal carcinogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.